Arena Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Arena Pharmaceuticals
Type Public (NASDAQARNA)
Industry Biotechnology
Headquarters San Diego, California, USA
Key people Jack Lief, cofounder and CEO
Dominic Behan, co-founder and senior scientist
Products in development
Revenue IncreaseUS$27.6M (FY 2012)[1]
Operating income DecreaseUS$-57M (FY 2012)[1]
Net income DecreaseUS$-85.5M (FY 2012)[1]
Total assets IncreaseUS$261M (FY 2012)[2]
Total equity IncreaseUS$98.6M (FY 2012)[2]

Arena Pharmaceuticals, Inc. is a biopharmaceutical company located in San Diego, California. The company is developing oral medications that target G-protein-coupled receptors. On June 27, 2012, the FDA approved lorcaserin, initially sold under the brand name Belviq.[3] Lorcaserin is approved for use in adults with a body mass index (BMI) of 30 or greater, which is considered obese, or adults with a BMI of 27 or greater and who have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol.

As of January 2009, Arena had other experimental drugs in their pipeline that have not yet been approved by the U.S. Food and Drug Administration, namely:

See also[edit]


  1. ^ a b c Arena Pharmaceuticals (ARNA) annual SEC income statement filing via Wikinvest.
  2. ^ a b Arena Pharmaceuticals (ARNA) annual SEC balance sheet filing via Wikinvest.
  3. ^ "FDA approves Belviq to treat some overweight or obese adults" (Press release). US FDA. June 27, 2012. Archived from the original on January 3, 2014. Retrieved January 3, 2014. 

External links[edit]